BC	Bladder cancer
BCG	Bacillus Calmette–Guérin
CK14	Cytokeratin 14
CK5/6	Cytokeratin 5/6
CI	Confidence interval
CSS	Cancer-specific survival
DDR	DNA damage response
EGFR	Epidermal growth factor receptor
EMT	Epithelial-to-mesenchymal transition
GATA3	GATA binding protein 3
HGT1	High-grade T1
HR	Hazard ratio
ICI	Immune checkpoint inhibitor
IHC	Immunohistochemistry
IO	Immunotherapy
MFS	Metastasis-free survival
MIBC	Muscle invasive bladder cancer
MPC	Micropapillary subtype carcinoma
MPUC	Micropapillary urothelial carcinoma
MSKCC	Memorial Sloan Kettering Cancer Center
MVUC	Muscle-invasive variant urothelial carcinoma
mRNA	Messenger RNA
NAC	Neoadjuvant cisplatin-based chemotherapy
NCDB	National Cancer Database
NMIBC	Non-muscle invasive bladder cancer
OS	Overall survival
PD-L1	Programmed death-ligand 1
PIK3CA	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
PCUC	Plasmacytoid variant
RB1	Retinoblastoma 1
RC	Radical cystectomy
RFS	Recurrence-free survival
S100P	S100 calcium-binding protein P
SBC	Histoligical subtype bladder cancer
SCC	Squamous cell carcinoma
SEER	Surveillance, Epidemiology, and End Results
SqD	Squamous differentiation
SUC	Sarcomatoid urothelial carcinoma
SUO	Society of Urologic Oncology
TERT	Telomerase reverse transcriptase
TP53	Tumor protein p53
UC	Urothelial carcinoma
UTI	Urinary tract infection
WHO	World Health Organization